| Nancy Reau MD, FAASLD, AGAF - 5/12/2017 |
Genotype 3 HCV infection is concerning, not just because of its natural history but also because of its potential role in reinfection. New data from EASL offer promise for the treatment of this challenging patient population.
Experimental Pangenotypic Therapies
When we consider the data presented for the next wave of HCV therapy, I believe we are approaching this objective. The currently approved pangenotypic fixed-dose combination of sofosbuvir (SOF)/velpatasvir (VEL) for 12 weeks offers high cure rates (95%) for genotype 3 HCV infection regardless of cirrhosis status. The 3 pangenotypic therapies in development promise even more options..
When we consider the data presented for the next wave of HCV therapy, I believe we are approaching this objective. The currently approved pangenotypic fixed-dose combination of sofosbuvir (SOF)/velpatasvir (VEL) for 12 weeks offers high cure rates (95%) for genotype 3 HCV infection regardless of cirrhosis status. The 3 pangenotypic therapies in development promise even more options..
Free registration required
No comments:
Post a Comment